All Stories

  1. Systematic Literature Review to Identify Influencing Factors of Efficacy and Safety Outcomes of Chimeric Antigen Receptor T-Cell Therapies in Large B-Cell Lymphoma

    Article • Blood, November 2023, American Society of Hematology

    Dr Jörg Mahlich

  2. Survival Outcomes of Patients with Diffuse Large B-Cell Lymphoma Who Received Autologous Stem Cell Transplantation in Germany - Real World Evidence from an Administrative Database

    Article • Blood, November 2023, American Society of Hematology

    Dr Jörg Mahlich

  3. The philosophy of pharmaceutical regulation—Paternalism or freedom of choice?

    Article • Frontiers in Medicine, October 2023, Frontiers

    Dr Jörg Mahlich

  4. Zahlungsbereitschaft für Insektizid-imprägnierte Moskitonetze zur Malariaprophylaxe in Subsahara-Afrika – eine systematische Literaturrecherche

    Article • Gesundheitsökonomie & Qualitätsmanagement, May 2023, Thieme Publishing Group

    Dr Jörg Mahlich

  5. Survival Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) - Real World Evidence from Germany

    Article • Blood, November 2022, American Society of Hematology

    Dr Jörg Mahlich

  6. Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma (DLBCL) - a Retrospective Health Claims Data Analysis

    Article • Blood, November 2022, American Society of Hematology

    Dr Jörg Mahlich

  7. Persistence With Biologic Therapy and Associated Costs of Patients With Inflammatory Bowel Disease: A German Retrospective Claims Data Analysis

    Article • Crohn s & Colitis 360, February 2021, Oxford University Press (OUP)

    Dr Jörg Mahlich

  8. Die Bedeutung von Big Data für klinische Entwicklungen und den Marktzugang

    Article • January 2020, Springer Science + Business Media

    Dr Jörg Mahlich

  9. Biologic treatment of Japanese patients with inflammatory bowel disease

    Article • BMC Gastroenterology, November 2018, Springer Science + Business Media

    Dr Jörg Mahlich

  10. Returns on different types of investment in the global pharmaceutical industry

    Article • Managerial and Decision Economics, October 2018, Wiley

    Dr Jörg Mahlich

  11. Burden of illness of chemotherapy in castration-resistant prostate cancer patients in Japan: a retrospective database analysis

    Article • Current Medical Research and Opinion, May 2018, Taylor & Francis

    Dr Jörg Mahlich

  12. Productivity loss of caregivers of schizophrenia patients: a cross-sectional survey in Japan

    Article • Journal of Mental Health, April 2018, Taylor & Francis

    Dr Jörg Mahlich

  13. Impact of patient characteristics and treatment procedures on hospitalization cost and length of stay in Japanese patients with influenza: A structural equation modelling approach

    Article • Influenza and Other Respiratory Viruses, October 2017, Wiley

    Dr Jörg Mahlich, Dr Hiroshi Kubo

  14. FRI0177 The underrated prevalence of depression in patients with rheumatoid arthritis

    Article • June 2017, BMJ

    Dr Jörg Mahlich

  15. Productivity and deadweight losses due to relapses of schizophrenia in Japan

    Article • May 2017, Dove Medical Press

    Dr Jörg Mahlich

  16. Treatment patterns of rheumatoid arthritis in Japanese hospitals and predictors of the initiation of biologic agents

    Article • Current Medical Research and Opinion, October 2016, Taylor & Francis

    Dr Jörg Mahlich

  17. Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan

    Article • Patient Preference and Adherence, August 2016, Dove Medical Press

    Dr Jörg Mahlich

  18. Treatment strategies for treatment naïve HIV patients in Germany: evidence from claims data

    Article • SpringerPlus, July 2015, Springer Science + Business Media

    Dr Jörg Mahlich

  19. Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan

    Article • ClinicoEconomics and Outcomes Research, May 2015, Dove Medical Press

    Dr Jörg Mahlich

  20. Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data

    Article • April 2015, Taylor & Francis

    Dr Jörg Mahlich

  21. A potential gender bias in assessing quality of life – a standard gamble experiment among university students

    Article • ClinicoEconomics and Outcomes Research, April 2015, Taylor & Francis

    Dr Jörg Mahlich

  22. Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan

    Article • Journal of Medical Economics, March 2015, Informa Healthcare

    Dr Jörg Mahlich

  23. Häufigkeiten antiretroviraler Therapie in Sekundärdaten von gesetzlichen Krankenkassen in Deutschland

    Article • Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen, January 2015, Elsevier

    Dr Jörg Mahlich

  24. Pharmaceutical regulation in Europe and its impact on corporate R&D

    Article • Health Economics Review, October 2014, Springer Science + Business Media

    Dr Jörg Mahlich

  25. Krankheitskosten von HIV-Patienten unter antiretroviraler Therapie in Deutschland – Ergebnisse einer 48-Wochen-Interimsanalyse im Rahmen der prospektiven multizentrischen Kohortenstudie „CORSAR“

    Article • Das Gesundheitswesen, September 2014, Thieme Publishing Group

    Dr Jörg Mahlich

  26. Evaluating the concordance of physician judgments and patient preferences on AIDS/HIV therapy - a Discrete Choice Experiment

    Article • Health Economics Review, December 2013, Springer Science + Business Media

    Dr Jörg Mahlich

  27. Budget Impact of Paliperidone Palmitate in Austria

    Article • Value in Health, November 2013, Elsevier

    Dr Jörg Mahlich

  28. Pharmaceutical Regulation in Europe and Its Impact on Corporate R&D

    Article • Value in Health, November 2013, Elsevier

    Dr Jörg Mahlich

  29. Cost-Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany

    Article • Value in Health, November 2013, Elsevier

    Dr Jörg Mahlich

  30. Erratum to: Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany

    Article • Applied Health Economics and Health Policy, September 2013, Springer Science + Business Media

    Dr Jörg Mahlich

  31. Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany

    Article • Applied Health Economics and Health Policy, August 2013, Springer Science + Business Media

    Dr Jörg Mahlich

  32. Medikamentenadhärenz in der Asthmatherapie - eine strukturierte Übersicht

    Article • Pneumologie, June 2013, Thieme Publishing Group

    Dr Jörg Mahlich

  33. Patient preferences for HIV/AIDS therapy - a discrete choice experiment

    Article • Health Economics Review, May 2013, Springer Science + Business Media

    Dr Jörg Mahlich

  34. Budget Impact Analyse von Paliperidon Palmitat im österreichischen Versorgungskontext

    Article • PharmacoEconomics German Research Articles, April 2013, Springer Science + Business Media

    Dr Jörg Mahlich

  35. PIH40 What Do Health Economists Expect from Their Employer- Results from an On-Line Survey in Germany

    Article • Value in Health, November 2012, Elsevier

    Dr Jörg Mahlich

  36. PMH18 Treatment Patterns and Costs in Patients With Schizophrenia in Germany

    Article • Value in Health, November 2012, Elsevier

    Dr Jörg Mahlich

  37. PIN33 Corsar-Study (Cost and Resource Utilisation Study in Antiretroviral Treated Patients)

    Article • Value in Health, November 2012, Elsevier

    Dr Jörg Mahlich

  38. Berufliche Erwartungen und Erfahrungen von angehenden und berufstätigen Gesundheitsökonomen - Ergebnisse einer online Umfrage

    Article • Gesundheitsökonomie & Qualitätsmanagement, October 2012, Thieme Publishing Group

    Dr Jörg Mahlich

  39. HIV/AIDS-Diagnosen und Verordnung von antiretroviraler Therapie in Deutschland – Häufigkeiten, Kosten und deren Bedeutung für die Kalkulation des morbiditätsorientierten Risikostrukturausgleichs

    Article • DMW - Deutsche Medizinische Wochenschrift, September 2012, Thieme Publishing Group

    Dr Jörg Mahlich

  40. Economic burden of osteoporotic fractures in Austria

    Article • Health Economics Review, June 2012, Springer Science + Business Media

    Dr Jörg Mahlich

  41. Direkte und indirekte Kosten von osteoporotisch bedingten Frakturen in Österreich

    Article • Das Gesundheitswesen, March 2012, Thieme Publishing Group

    Dr Jörg Mahlich

  42. Korean Science and Technology in an International Perspective

    Article • January 2012, Springer Science + Business Media

    Dr Jörg Mahlich

  43. PHP138 Intangible Capital and Return on Assets in the Pharmaceutical Industry

    Article • Value in Health, November 2011, Elsevier

    Dr Jörg Mahlich

  44. Institutionelle Determinanten von F&E-Investitionen

    Article • Journal of Business Economics, August 2011, Springer Science + Business Media

    Dr Jörg Mahlich

  45. Introduction: The Challenge of Innovation and Technology for Korea as a Newly Advanced Economy Revisited

    Article • July 2011, Springer Science + Business Media

    Dr Jörg Mahlich

  46. R&D MANAGEMENT OF JAPANESE PHARMACEUTICAL FIRMS

    Article • International Journal of Innovation and Technology Management, June 2011, World Scientific Pub Co Pte Lt

    Dr Jörg Mahlich

  47. Intangibles Kapital und Rentabilität in der Pharmaindustrie

    Article • Die Unternehmung, January 2011, Nomos Verlag

    Dr Jörg Mahlich

  48. Wettbewerb zwischen Generika und Originalherstellern in Österreich am Beispiel der ACE-Hemmer

    Article • Das Gesundheitswesen, December 2010, Thieme Publishing Group

    Dr Jörg Mahlich

  49. PMS23 BURDEN OF ILLNESS OF OSTEOPOROSIS IN AUSTRIA

    Article • Value in Health, November 2010, Elsevier

    Dr Jörg Mahlich

  50. Patents and performance in the Japanese pharmaceutical industry: An institution-based view

    Article • Asia Pacific Journal of Management, January 2009, Springer Science + Business Media

    Dr Jörg Mahlich

  51. The Japanese Pharmaceutical Industry in Transition: Has Higher Research Orientation Resulted in Higher Market Value?

    Article • Asian Business & Management, February 2007, Springer Science + Business Media

    Dr Jörg Mahlich

  52. Innovation and Technology in Korea

    Article • January 2007, Springer Science + Business Media

    Dr Jörg Mahlich

  53. The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan

    Article • Review of Industrial Organization, March 2006, Springer Science + Business Media

    Dr Jörg Mahlich

  54. Anmerkungen zur Profitabilität der Pharmaindustrie

    Article • WiSt - Wirtschaftswissenschaftliches Studium, January 2006, Verlag Franz Vahlen GmbH

    Dr Jörg Mahlich

  55. Wirtschaftspolitik für wissensintensive Branchen am Beispiel der Pharmaindustrie

    Article • Zeitschrift für Wirtschaftspolitik, December 2005, De Gruyter

    Dr Jörg Mahlich

  56. Die japanische Pharmaindustrie

    Article • Springer Science + Business Media

    Dr Jörg Mahlich

  57. Introduction: Korea as a Newly Advanced Economy and the Role of Technology and Innovation

    Article • Springer Science + Business Media

    Dr Jörg Mahlich

  58. The Technological Competencies of Korea’s Firms: A Patent Analysis

    Article • Springer Science + Business Media

    Dr Jörg Mahlich